Advertisement Crucell and Medarex sign research license agreement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Crucell and Medarex sign research license agreement

Dutch biotechnology company Crucell has announced a non-exclusive Star research license agreement with biopharmaceutical company Medarex for the production of monoclonal antibodies.

Star technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell’s PER.C6 human cell technology and the widely used Chinese hamster ovary cell line.